Atreca Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
This is Josh Schimmer from the Evercore ISI Biotech team. Very pleased to introduce. From Atreca, we have John Orwin, President and Chief Executive Officer; Steven Gould, Chief Scientific Officer; Herb Cross, Chief Financial Officer; Tito Serafini, Chief Strategy Officer; and we also have Alex Gray from Corporate Communications with us.
So gentlemen, welcome. Thanks so much for joining. Why don't we just kind of start with a snapshot of Atreca's platform and where you are in that division kind of company.
Sure. And I'll take that one unless you want to dive deeper into the platform. But essentially, we have a validated platform that allows us to discover novel antibody target pairs by interrogating the human immune response platform involves high-throughput sequencing of B cell plasmablasts of our serial samples so that we can look at the emergence or expansion or persistence of different B cell clones that help us to identify antibodies that may be important in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |